



EDITORIAL

Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF

Hongquan Wang*, Shuang Wu*, Yan Wang, Bo Tang

Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

Pancreatic ductal adenocarcinoma (PDAC), the most common histologic type of pancreatic cancer, is among the most lethal cancers, and is associated with poor prognosis because of its inherent chemoresistant nature and metastatic capacity¹. Extensive evidence has shown that cancer stem cells (CSCs), a subpopulation of highly plastic “stem”-like cells within the PDAC, mediate this chemoresistance and metastatic capacity². CSCs have unique metabolic, invasive, and chemoresistance properties that enable them to continually self-renew and escape standard chemotherapeutic elimination in PDAC, thus often rendering treatments ineffective^{3,4}.

Ongoing investigations have indicated that CSCs are regulated by both cell-intrinsic signaling pathways and cell-extrinsic factors derived from stromal cells^{5,6}. Pancreatic stellate cells (PSCs), the major cell types in the PDAC stroma, show abundant desmoplasia, which promotes cancer cell aggressiveness and resistance to anti-cancer drugs. These important cell-extrinsic factors secrete prostemness cytokines, thereby forming the CSC niche and participating in active crosstalk with cancer cells within the tumor microenvironment⁷⁻⁹. Consequently, targeted attenuation of PSC activation is a promising therapeutic strategy to inhibit tumor-stromal interactions with pancreatic cancer cells^{7,10}. However, current anti-CSC therapeutic strategies focus mainly on targeting cell-intrinsic stemness-associated genes, which are shared by CSCs and normal stem cells, thus resulting in adverse effects.

Consequently, an urgent need exists to understand the complexity of stromal expansion and dysfunctional tumor immunity to develop effective therapies for PDAC.

A study published in *Gut* by Zhou et al.¹¹ demonstrates that epithelium-specific E26 transformation-specific (ETS) factor family member 3 or ESE3/E26 transformation-specific homologous factor (ESE3/EHF) functions as a tumor cell-intrinsic and cell-extrinsic master transcription factor that disrupts the crosstalk between CSCs and the PSC-derived CSC-supportive niche by negatively regulating the CXCL12 receptor CXCR4 in tumors. Targeting of ESE3/EHF by rosiglitazone thus provides an alternative strategy to induce PDAC regression¹¹ (**Figure 1**).

ESE3/EHF, a member of the Ets family of transcription factors, is a tumor suppressor transcription factor^{12,13} that is crucial in differentiation and development programs for many epithelial tissues, and plays an important role in cancer development¹⁴. ESE3/EHF is frequently down-regulated in several malignancies, and is involved in carcinogenesis and progression¹⁵. Setting the stage for these new findings, Zhao et al.¹⁶ first suggested a role of ESE3/EHF in PDAC development and progression (**Figure 1A**). In their early work, the authors showed that the expression of ESE3/EHF is markedly diminished in PDAC, and is closely correlated with lymph node metastasis, vessel invasion, and attenuated relapse-free and overall survival in patients. Downregulation of ESE3/EHF has been found to promote PDAC cell motility and invasiveness, together with metastasis, in an orthotopic mouse model. Mechanistic studies have indicated that ESE3/EHF inhibits PDAC metastasis through direct transcriptional upregulation of E-cadherin expression in PDAC cell lines and an orthotopic mouse model. Moreover, in human PDAC specimens, ESE3/EHF has been found to inhibit PDAC metastasis through direct transcriptional upregulation of E-cadherin expression¹⁶. Extending these findings, the authors have demonstrated that ESE3/EHF has novel roles in addition of

*These authors contributed equally to this work.

Correspondence to: Bo Tang

E-mail: tangbo@tmu.edu.cn

ORCID ID: <https://orcid.org/0000-0002-3568-6925>

Received June 2, 2022; accepted June 15, 2022;

published online July 21, 2022.

Available at www.cancerbiomed.org

©2022 Cancer Biology & Medicine. Creative Commons

Attribution-NonCommercial 4.0 International License




Figure 1 Schematic depiction of the roles of the tumor suppressor ESE3/EHF in PDAC. (A) ESE3/EHF inhibits PDAC metastasis through direct transcriptional upregulation of E-cadherin expression in PDAC¹⁶. (B) ESE3/EHF decreases tumor-infiltrating T reg cells and MDSCs through transcriptional suppression of the expression of TGFβ1 and GM-CSF¹⁷. (C) ESE3/EHF is a tumor cell-intrinsic and tumor cell-extrinsic master transcription factor that disrupts the crosstalk between CSCs and their PSC-derived CSC-supportive niche by negatively regulating tumor CXCR4. Targeting ESE3/EHF by rosiglitazone provides an alternative strategy to induce PDAC regression¹¹.

pancreatic cancer immune microenvironment and prediction of the efficacy of anti-PD1 therapy. Loss of tumoral ESE3/EHF induces accumulation of regulatory T (T reg) cells and myeloid-derived suppressor cells (MDSCs), and decreases the number of tumor-infiltrating CD8⁺ T cells. Mechanistic studies have demonstrated that ESE3/EHF deficiency induces the conversion and expansion of T reg cells and MDSCs through inhibition of tumor TGFβ1 and GM-CSF secretion, respectively. EHF

suppresses the transcription of TGFβ1 and GM-CSF by directly binding their promoters. Mice bearing ESE3/EHF overexpressing tumors show a significantly better response to anti-PD1 therapy than mice bearing control tumors. These findings have indicated the immunosuppressive mechanism of ESE3/EHF deficiency in PDAC, thus highlighting that ESE3/EHF overexpression may improve PDAC checkpoint immunotherapy¹⁷ (Figure 1B).

Using LSL-Kras^{G12D/+} mice, a LSL-Trp53^{R172H/+} and Pdx1-Cre (KPC) mouse model, and samples from patients with PDAC, Zhou et al.¹¹ have provided the first evidence that ESE3/EHF acts as a driver of malignant tumor progression, and suppresses cancer stemness through both cancer cell-intrinsic and cancer cell-extrinsic mechanisms. These findings provide a compelling rationale for therapeutic targeting of ESE3/EHF. In their studies, the authors have demonstrated that ESE3/EHF represses the expression of SOX9, SOX2, OCT4, and Nanog in the cell-intrinsic pathway. Simultaneously, ESE3/EHF decreases the sensitivity of PDACs to stimuli from the PSC-derived CSC-supportive niche by negatively regulating tumor CXCR4 expression in the cell-extrinsic pathway¹¹. Rosiglitazone could conceivably be used to target pancreatic stem cells and the crosstalk between CSCs and their niche by upregulating ESE3/EHF¹¹. Rosiglitazone, a specific PPAR- γ agonist that improves glycemic control and insulin sensitivity in patients with diabetes by selectively activating PPAR- γ , inhibits PDAC stemness and suppresses sensitivity to stemness-promoting stimuli by upregulating ESE3/EHF expression. Additionally, rosiglitazone has been found to sensitize PDAC to gemcitabine therapy in a KPC mouse model. Together, these findings elucidate how ESE3/EHF mediates the crosstalk between pancreatic cancer and its PSC-associated stemness-supporting niche. Developing therapies targeting this crosstalk through modulation of ESE3/EHF by rosiglitazone may be feasible and would have great therapeutic potential (Figure 1C).

Grant support

This editorial was supported partly by the National Natural Science Foundation of China (Grant Nos. 81871938 and 82173118), Guangxi Natural Science Foundation for Key Program of Research & Development (Grant No. GuiKe AB21075003), and Guangxi Natural Science Foundation for Guangdong-Guangxi United Program (Grant No. 2021GXNSFDA075014).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. Lambert A, Conroy T, Ducreux M. Future directions in drug development in pancreatic cancer. *Semin Oncol.* 2021; 48: 47-56.

2. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. *Mol Cell.* 2014; 54: 716-27.
3. Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem cells in the exocrine pancreas during homeostasis, injury, and cancer. *Cancers (Basel).* 2021; 13: 3295.
4. Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. *Nat Rev Cancer.* 2021; 21: 526-36.
5. Oshimori N, Guo Y, Taniguchi S. An emerging role for cellular crosstalk in the cancer stem cell niche. *J Pathol.* 2021; 254: 384-94.
6. Chan TS, Shaked Y, Tsai KK. Targeting the interplay between cancer fibroblasts, mesenchymal stem cells, and cancer stem cells in desmoplastic cancers. *Front Oncol.* 2019; 9: 688.
7. Sagara A, Nakata K, Yamashita T, Guan W, Zhong P, Matsumoto S, et al. New high-throughput screening detects compounds that suppress pancreatic stellate cell activation and attenuate pancreatic cancer growth. *Pancreatol.* 2021; S1424-3903(21)00141-1: Online ahead of print. doi: 10.1016/j.pan.2021.04.002.
8. Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, et al. Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. *Cancer Res.* 2019; 79: 5723-33.
9. Wu Y, Zhang C, Jiang K, Werner J, Bazhin AV, D'Haese JG. The role of stellate cells in pancreatic ductal adenocarcinoma: targeting perspectives. *Front Oncol.* 2020; 10: 621937.
10. Chen X, Zhang Y, Qian W, Han L, Li W, Duan W, et al. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. *iScience.* 2021; 24: 103400.
11. Zhou T, Liu J, Xie Y, Yuan S, Guo Y, Bai W, et al. ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. *Gut.* 2022; 71: 357-71.
12. Jha NN, Kumar R, Panigrahi R, Navalkar A, Ghosh D, Sahay S, et al. Comparison of α -Synuclein fibril inhibition by four different amyloid inhibitors. *ACS Chem Neurosci.* 2017; 8: 2722-33.
13. Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G, et al. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. *Cancer Res.* 2012; 72: 2889-900.
14. Li J, Yang J, Hua L, Wang R, Li H, Zhang C, et al. ESE-3 contributes to colon cancer progression by downregulating EHD2 and transactivating INPP4B. *Am J Cancer Res.* 2021; 11: 92-107.
15. Lyu Z, Ma M, Xu Y, Wang X, Zhu Y, Ren W, et al. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. *Int J Clin Oncol.* 2020; 25: 1334-45.
16. Zhao T, Jiang W, Wang X, Wang H, Zheng C, Li Y, et al. ESE3 Inhibits pancreatic cancer metastasis by upregulating E-cadherin. *Cancer Res.* 2017; 77: 874-85.
17. Liu J, Jiang W, Zhao K, Wang H, Zhou T, Bai W, et al. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma. *J Exp Med.* 2019; 216: 656-73.

Cite this article as: Wang H, Wu S, Wang Y, Tang B. Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF. *Cancer Biol Med.* 2022; 19: 945-947. doi: 10.20892/j.issn.2095-3941.2022.0299